New triple therapy aims to tame melanoma treatment's worst side effects
NCT ID NCT03999749
First seen Mar 28, 2026 · Last updated Jun 17, 2026 · Updated 11 times
Summary
This study tests whether adding tocilizumab to standard immunotherapy (ipilimumab + nivolumab) can reduce severe immune-related side effects in people with advanced melanoma that cannot be removed by surgery. About 71 participants will receive the three-drug combination during an induction phase, followed by maintenance nivolumab alone for up to one year. The main goals are to measure safety and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
The Angeles Clinic
Los Angeles, California, 90025, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.